Rhabdomyosarcoma — Trials

Rhabdomyosarcoma — Trials · CancerIndex

Clinical trials

Registered studies

210 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 74
Recruiting: 37
Ph III recruiting: 4
Growth YoY: —
Industry share: 9%
Top sponsor: National Cancer Institute (NCI)
Termination share: 25%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (22)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02013336	Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors	unknown	Phase 1	30	South Plains Oncology ConsortiumNETWORK	1	Mar 31, 2022	clinicaltrials
NCT02409576	Pilot Study of Expanded , Activated Haploidentical Natural Killer Cell Infusions for Sarcomas(NKEXPSARC)	unknown	Phase 1 / Phase 2	20	National University Hospital, SingaporeOTHER